Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
CLBE-stem cell/rumor on microbank opening!PR anytime
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by pennyaddict71: [QB] I placed an order today for some CLBE, it was very thin from .056 to .07, people are holding strong at .07. Once we get volume this stock will take off quick, my order moved the stock price over 20% LOL. I agree with Quest when he says this is one of the most undervalued BB stocks in the market.. very safe place to have your money parked IMO. From: SessionsIR.com SessionsIR.com: Genentech Named Best Firm by Fortune: CLBE, STEM, YMI, SNY, DNA (CLBE) is a great mid-long term investment. They just recently reported a significant increase in revenues for the past 9 months. With another profitable quarter, this one could break out to new trading ranges. This is a not another junky catchpenny. They sell quality products and are engaged in a business that will play a huge roll in stem cell developments these next few years. Here are some the quotes from their recent 10K: -Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients." -After the acquisition of KD Medical, the Research Reagents Division has two companies with combined 2004 revenues of approximately $1.2 Million in gross revenues. Within three years, it is anticipated that revenues will grow to $5 Million. -The Company anticipates the launch of LifeStem's stem cell MicroBank in the first quarter of 2006, which the Company believes will lead to significant additional revenue. CalbaTech, Inc. ( OTC:CLBE) has made impressive strides in the last year. As well as acquiring KD Medical, the company generated substantially increased revenues of $952,312 in the first three quarters of 2005, up from $128,940 during the same period last year, an increase of over 600%. The company is understandably pleased, particularly since operating expenses remained relatively steady, allowing for acquisition and financing costs, despite the significantly increased activity. CalbaTech, Inc.. The Group's principal activities are to provide products and platforms to the life sciences research market, both for biotech and pharmaceutical companies. The customers include federally funded research centers, supply stores, university and private research centers, medical distributors and Original Equipment Manufacturers. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2